508 research outputs found
Applications of inertial navigation and modern control theory to the all weather landing problem
Inertial navigation and automatic landing control theory applied to instrument landing proble
Politics as a Sphere of Wealth Accumulation: Cases of Gilded Age New York, 1855-1888
This dissertation examines political wealth accumulation in American political development. Scholars have long understood the political system selects for progressive ambition for higher office. My research shows that officeseekers have also engaged in progressive greed for greater wealth. I compare the career trajectories of four prominent New York political figures during the Gilded Age: William Tweed, Fernando Wood, Roscoe Conkling, and Chester Arthur. Using correspondence, census, tax and land records, government reports, investigations, and newspaper coverage, I explain why each political figure chose to either seize or pass up opportunities for political wealth accumulation. I also examine the principal sources of fortunes and the types of political practices that generated them.
Profit-maximizing behavior during the late nineteenth century was central to the consolidation of politics as a vocation. Career-altering events such as an election loss, or alternatively, the opportunity to join a dominant party faction, often recalibrated a politician\u27s strategic calculation in the tradeoff between power and wealth. Furthermore, the dominant view of self-aggrandizement is that public officials either steal or extract rents, for example, in the form of bribes or loans. However, none of the large fortunes examined among my cases were built through conventional rent seeking, and peculation was only a minor source of income. Instead, the great fortunes were built through marketing-making activities. Tweed, Wood, Conkling, and Arthur accumulated political wealth by securing dominant market positions, or by creating new markets altogether. These figures accumulated productive personal property, or political capital, through control over political institutions, most notably by speculating in real estate, railroads, and finance, and by the establishment of politically dependent businesses, such as banks, lotteries, newspapers, and law firms
Modeling Sitagliptin Effect on Dipeptidyl Peptidase 4 (DPP4) Activity in Adults with Hematological Malignancies After Umbilical Cord Blood (UCB) Hematopoietic Cell Transplant (HCT)
Background and Objectives—
Dipeptidyl peptidase-4 (DPP4) inhibition is a potential strategy
to increase the engraftment rate of hematopoietic stem/progenitor cells. A recent clinical trial
using sitagliptin, a DPP4 inhibitor approved for type 2 diabetes mellitus, has shown to be a
promising approach in adults with hematological malignancies after umbilical cord blood (UCB)
hematopoietic cell transplant (HCT). Based on data from this clinical trial, a semi-mechanistic
model was developed to simultaneously describe DPP4 activity after multiple doses of sitagliptin
in subjects with hematological malignancies after a single-unit UCB HCT.
Methods—
The clinical study included 24 patients that received myeloablative conditioning
followed by 4 oral sitagliptin 600mg with single-unit UCB HCT. Using a nonlinear mixed effects
approach, a semi-mechanistic pharmacokinetic/pharmacodynamic model was developed to
describe DPP4 activity from this trial data using NONMEM 7.2. The model was used to drive
Monte-Carlo simulations to probe various dosage schedules and the attendant DPP4 response.
Results—
The disposition of sitagliptin in plasma was best described by a 2-compartment model.
The relationship between sitagliptin concentration and DPP4 activity was best described by an
indirect response model with a negative feedback loop. Simulations showed that twice a day or
three times a day dosage schedules were superior to once daily schedule for maximal DPP4
inhibition at the lowest sitagliptin exposure.
Conclusion—
This study provides the first pharmacokinetic/pharmacodynamic model of
sitagliptin in the context of HCT, and provides a valuable tool for exploration of optimal dosing
regimens, critical for improving time to engraftment in patients after UCB HCT
Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells.
Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34+ cells in a murine model of umbilical cord blood transplantation
Delayed engraftment and graft failure represent major obstacles to successful umbilical cord blood (UCB) transplantation. Herein, we evaluated the use of hyperbaric oxygen (HBO) therapy as an intervention to improve human UCB stem/progenitor cell engraftment in an immune deficient mouse model. Six-to eight-week old NSG mice were sublethally irradiated 24 hours prior to CD34+ UCB cell transplant. Irradiated mice were separated into a non-HBO group (where mice remained under normoxic conditions) and the HBO group (where mice received two hours of HBO therapy; 100% oxygen at 2.5 atmospheres absolute). Four hours after completing HBO therapy, both groups intravenously received CD34+ UCB cells that were transduced with a lentivirus carrying luciferase gene and expanded for in vivo imaging. Mice were imaged and then sacrificed at one of 10 times up to 4.5 months post-transplant. HBO treated mice demonstrated significantly improved bone marrow, peripheral blood , and spleen (p=0.0293) retention and subsequent engraftment. In addition, HBO significantly improved peripheral, spleen and bone marrow engraftment of human myeloid and B-cell subsets. In vivo imaging demonstrated that HBO mice had significantly higher ventral and dorsal bioluminescence values. These studies suggest that HBO treatment of NSG mice prior to UCB CD34+ cell infusion significantly improves engraftment
Genotoxic stresses promote clonal expansion of hematopoietic stem cells expressing mutant p53
High-dose Sitagliptin for Systemic Inhibition of Dipeptidylpeptidase-4 to Enhance Engraftment of Single Cord Umbilical Cord Blood Transplantation
Delayed engraftment remains a limitation of umbilical cord blood (UCB) transplantation. We previously showed that inhibition of dipeptidylpeptidase (DPP)-4 using sitagliptin 600 mg daily was safe with encouraging results on engraftment, but inhibition was not sustained. We evaluated the efficacy and feasibility of higher doses of sitagliptin to enhance engraftment of UCB in patients with hematological cancers. Fifteen patients, median age 41 (range, 18-59) years, received single UCB grafts matched at 4 (n=11) or 5 (n=4) of 6 HLA loci with median nucleated cell dose of 3.5 (range, 2.57-4.57) x10(7)/kg. Sitagliptin 600 mg every 12 hours was administered days -1 to +2. All patients engrafted by day 30, with 12 (80%) engrafting by day 21. The median time to neutrophil engraftment was 19 (range, 12-30) days. Plasma DPP-4 activity was better inhibited with a mean residual trough DPP-4 activity of 70%+/-19%. Compared to patients previously treated with 600 mg/day, sitagliptin 600 mg every 12 hours appeared to improve engraftment, supporting the hypothesis that more sustained DPP-4 inhibition is required. In-vivo inhibition of DPP-4 using high-dose sitagliptin compares favorably with other approaches to enhance UCB engraftment with greater simplicity, and may show synergy in combination with other strategies
The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
Mobilized blood has supplanted bone marrow (BM) as the primary source of hematopoietic stem cells for autologous and allogeneic stem cell transplantation. Pharmacologically enforced egress of hematopoietic stem cells from BM, or mobilization, has been achieved by directly or indirectly targeting the CXCL12/CXCR4 axis. Shortcomings of the standard mobilizing agent, granulocyte colony-stimulating factor (G-CSF), administered alone or in combination with the only approved CXCR4 antagonist, Plerixafor, continue to fuel the quest for new mobilizing agents. Using Protein Epitope Mimetics technology, a novel peptidic CXCR4 antagonist, POL5551, was developed. In vitro data presented herein indicate high affinity to and specificity for CXCR4. POL5551 exhibited rapid mobilization kinetics and unprecedented efficiency in C57BL/6 mice, exceeding that of Plerixafor and at higher doses also of G-CSF. POL5551-mobilized stem cells demonstrated adequate transplantation properties. In contrast to G-CSF, POL5551 did not induce major morphological changes in the BM of mice. Moreover, we provide evidence of direct POL5551 binding to hematopoietic stem and progenitor cells (HSPCs) in vivo, strengthening the hypothesis that CXCR4 antagonists mediate mobilization by direct targeting of HSPCs. In summary, POL5551 is a potent mobilizing agent for HSPCs in mice with promising therapeutic potential if these data can be orroborated in humans
Potency analysis of cellular therapies: the emerging role of molecular assays
Potency testing is an important part of the evaluation of cellular therapy products. Potency assays are quantitative measures of a product-specific biological activity that is linked to a relevant biological property and, ideally, a product's in vivo mechanism of action. Both in vivo and in vitro assays can be used for potency testing. Since there is often a limited period of time between the completion of production and the release from the laboratory for administration to the patient, in vitro assays such are flow cytometry, ELISA, and cytotoxicity are typically used. Better potency assays are needed to assess the complex and multiple functions of cellular therapy products, some of which are not well understood. Gene expression profiling using microarray technology has been widely and effectively used to assess changes of cells in response to stimuli and to classify cancers. Preliminary studies have shown that the expression of noncoding microRNA which play an important role in cellular development, differentiation, metabolism and signal transduction can distinguish different types of stem cells and leukocytes. Both gene and microRNA expression profiling have the potential to be important tools for testing the potency of cellular therapies. Potency testing, the complexities associated with potency testing of cellular therapies, and the potential role of gene and microRNA expression microarrays in potency testing of cellular therapies is discussed
The Brain: Is it a Next Frontier to Better Understand the Regulation and Control of Hematopoiesis for Future Modulation and Treatment?
We wish to suggest the possibility there is a link between the brain and hematopoiesis in the bone marrow and that in the future it may be possible to use such information for better understanding of the regulation of hematopoiesis, and for efficacious treatment of hematopoietic disorders
- …